Biogen (BIIB) Set to Post Quarterly Earnings on Wednesday

Biogen (NASDAQ:BIIB) is anticipated to announce its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect Biogen to post earnings of $1.98 per share and revenue of $2.63 billion for the quarter. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:30 AM ET.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%. The firm had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. During the same quarter in the prior year, the firm posted $5.47 earnings per share. The company’s quarterly revenue was up 3.4% on a year-over-year basis. On average, analysts expect Biogen to post $12.29 EPS for the current fiscal year and $16.08 EPS for the next fiscal year.

Biogen Price Performance

Shares of BIIB stock opened at $252.26 on Tuesday. Biogen has a 52-week low of $138.00 and a 52-week high of $254.41. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The firm has a market capitalization of $37.27 billion, a P/E ratio of 17.94, a P/E/G ratio of 2.99 and a beta of 0.09. The stock has a 50 day moving average price of $223.38 and a 200 day moving average price of $199.43.

Analysts Set New Price Targets

Several equities analysts have commented on BIIB shares. Morgan Stanley upped their price objective on Biogen from $222.00 to $231.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Royal Bank Of Canada decreased their target price on Biogen from $260.00 to $256.00 and set an “outperform” rating for the company in a research report on Thursday, October 8th. HSBC lifted their target price on Biogen from $165.00 to $175.00 and gave the stock a “reduce” rating in a research report on Thursday, September 10th. TD Cowen boosted their target price on shares of Biogen from $225.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. Finally, Citigroup upped their price target on shares of Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $241.89.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.